Revolutionary Scientists Honored for Advancements in Gene Therapy for Neuromuscular Diseases and RNA Discoveries: King Faisal Prize Laureates in Medicine, Professor Jerry Mendell, and in Science, Professor Howard Chang, Awarded
22 avr. 2024 15h29 HE
|
King Faisal Foundation
Riyadh, Saudi Arabia, April 22, 2024 (GLOBE NEWSWIRE) -- During the 46th session of King Faisal Prize on April 22, exceptional accomplishments in the fields of gene therapy for neuromuscular...
Natural Killer (NK) Cell Therapy Pipeline Research Report 2024: Comprehensive Insights About 100+ Companies and 185+ Pipeline Drugs
19 avr. 2024 07h35 HE
|
Research and Markets
Dublin, April 19, 2024 (GLOBE NEWSWIRE) -- The "Natural Killer (NK) cell therapy - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This "Natural Killer...
AAV Vectors in Gene Therapy Pipeline Landscape Report 2024: Comprehensive Insights about 70+ Companies and 235+ Pipeline Drugs
19 avr. 2024 07h31 HE
|
Research and Markets
Dublin, April 19, 2024 (GLOBE NEWSWIRE) -- The "AAV vectors in gene therapy - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering.This "AAV vectors in gene...
Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy
19 avr. 2024 07h13 HE
|
Ocugen
MALVERN, Pa., April 19, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets
12 avr. 2024 07h30 HE
|
Ocugen
MALVERN, Pa., April 12, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
Sania Therapeutics to Present at the American Society of Gene & Cell Therapy Annual Meeting
11 avr. 2024 07h00 HE
|
Sania Therapeutics
Sania Therapeutics to Present at the American Society of Gene & Cell Therapy Annual Meeting LONDON, UK & NEW YORK, USA – 11 April 2024, Sania Therapeutics (the “Company”), focused on...
ViGeneron Announces First Patient Dosed in Phase 1b Clinical Trial of VG901 for the Intravitreal Treatment of Retinitis Pigmentosa
10 avr. 2024 05h03 HE
|
ViGeneron GmbH
VG901 is the first and only clinical-stage therapy designed to deliver a functional CNGA1 gene to retinal photoreceptor target cells in retinitis pigmentosa patientsVG901, using ViGeneron’s...
Epic Bio Announces Robust Slate of Presentations at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting
09 avr. 2024 09h00 HE
|
Epic Bio
SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Epic Bio, a leading epigenetic editing company that plans to have its FSHD program enter the clinic this year, today announced the...
Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication
08 avr. 2024 06h30 HE
|
Ocugen
MALVERN, Pa., April 08, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
Global Cell and Gene Therapy Markets Report 2024-2028 Featuring Main Players - Mallinckrodt, Vericel, Gilead Sciences, Pharmicell, and Bristol-Myers Squibb
03 avr. 2024 03h10 HE
|
Research and Markets
Dublin, April 03, 2024 (GLOBE NEWSWIRE) -- The "Global Cell and Gene Therapy Market" report has been added to ResearchAndMarkets.com's offering. The Global Cell and Gene Therapy Market is...